Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Contraceptives can be used after sex to stop a pregnancy before it starts. There are two main types of emergency contraception: Emergency contraceptive pills (ECPs) and copper T intrauterine device (IUD).

The global contraceptives market is estimated to account for US$ 25,969.2 Mn in terms of value in 2020 and is expected to reach US$ 37,889.0 Mn by the end of 2027.

Global Contraceptives Market: Drivers

Increasing population is expected to propel growth of the global emergency contraceptives market over the forecast period. For instance, according to projections by Population Reference Bureau (PRB) included in the 2018 World Population Data Sheet, the world population is expected to reach 9.9 billion by 2050, up 2.3 billion or 29% from an estimated 7.6 billion people in 2018.

Moreover, increasing focus on family planning among the populace is also expected to aid in growth of the market. For instance, according to PRB’s 2019 Family Planning Data Sheet, globally, 62% of married women ages 15 to 49 use a method of family planning and 56% use a modern method.

Devices held dominant position in the global contraceptives market in 2019, accounting for 57.2% share in terms of value, followed by drugs, respectively

Figure 1. Global Contraceptives Market Share (%), by Value, by Type, 2019

Contraceptives  | Coherent Market Insights

Global Contraceptives Market: Restraints

Side effects associated with the use of contraceptive drugs and devices are expected to hinder growth of the global contraceptives market. Long term side effects associated with oral contraceptive pills such as increased risk of breast cancer, blood clots, and heart strokes strongly discourage usage.

Moreover, low adoption of emergency contraceptives in emerging economies is expected to hinder growth of the market. For instance, according to PRB’s 2019 Family Planning Data Sheet, fewer than 15% of married women of reproductive age use a modern contraceptives in Democratic Republic of the Congo. 

request-sample

Contraceptives Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 24,605.4 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.5% 2027 Value Projection: US$ 37,889.0 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Type:
    • Drugs: Oral Contraceptive Pills, Injectables, Topical
    • Devices: Male Condoms, Female Condoms, Diaphragms, Sponges, Vaginal Rings, Subdermal Implants, IUD
Companies covered:

Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., and Pantarhei Bioscience B.V.

Growth Drivers:
  • Increasing population
  • Increasing focus on family planning
Restraints & Challenges:
  • Side effects of drugs and devices
  • Low adoption of emergency contraceptives in emerging economies

Global Contraceptives Market: Opportunities

Increasing rate of literacy is expected to offer lucrative growth opportunities for players in the global contraceptives market. For instance, according to United Nations Children's Fund, globally, the youth literacy rate increased from 83% to 91% during 1985-2018.

Moreover, high prevalence of HIV/AIDS is expected to boost demand for contraceptives. For instance, according to UNAIDS Global HIV & AIDS statistics — 2019 fact sheet, 37.9 million people were infected with HIV worldwide. 

The global contraceptives market was valued at US$ 24,605.4 Mn in 2019 and is forecast to reach a value of US$ 37,889.0 Mn by 2027 at a CAGR of 5.5% between 2020 and 2027.

Figure 2. Global Contraceptives Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Contraceptives  | Coherent Market Insights

Market Trends/Key Takeaways

Major contraceptive drugs are nearing patent expiry, which is expected to make way for generics. For instance, patent for YAZ (drospirenone/ethinylestradiol), which provides an oral contraceptive regimen, is set to expire in 2021.  

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in February 2020, Agile Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its Twirla (levonorgestrel and ethinyl estradiol) transdermal system indicated as a method of contraception for use in women.

Global Contraceptives Market: Competitive Landscape

Major players operating in the global emergency contraceptives market include, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., and Pantarhei Bioscience B.V.

Global Contraceptives Market: Key Developments

Major players in the market are focused on raising funds to expand their product portfolio. For instance, in April 2020, Evofem Biosciences, Inc. entered into a private Securities Purchase Agreement with a U.S.-based, healthcare-focused institutional investor for up to US$ 25 million of convertible notes.

Contraceptive drugs and devices that aid to control birth rate and unintended pregnancies are subject to unique regulatory challenges across different countries. For instance, contraceptive drugs and devices face reimbursement challenges in the U.S., while contraceptive pills face advertising restrictions in India. Owing to this, contraceptives preference greatly various across countries. Statistics revealed by the United Nations in 2015, highlight this trends, with a particular contraceptive accounting for over 50% share across 45 countries considered in the study. Sterilization is a dominant contraceptive method in regions such as Asia, North America, and Latin America as per the study.

Restraints of the Global Contraceptives Market

Major factors hampering the growth of the contraceptives market during the forecast period constitutes of side effects associated with drugs and devices, and low adoption of emergency contraceptives in emerging economies.

Key features of the study:

  • This report provides in-depth analysis of the global contraceptives market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global contraceptives market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., and Pantarhei Bioscience B.V.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global contraceptives market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Contraceptives Market, By Type:
    • Drugs
      • Oral Contraceptive Pills
      • Injectables
      • Topical
    • Devices
      • Male Condoms
      • Female Condoms
      • Diaphragms
      • Sponges
      • Vaginal Rings
      • Subdermal Implants
      • IUD
  • Global Contraceptives Market, By Geography:
    • North America
      • By Type
        • Drugs
          • Oral Contraceptive Pills
          • Injectables
          • Topical
        • Devices
          • Male Condoms
          • Female Condoms
          • Diaphragms
          • Sponges
          • Vaginal Rings
          • Subdermal Implants
          • IUD
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Type
        • Drugs
          • Oral Contraceptive Pills
          • Injectables
          • Topical
        • Devices
          • Male Condoms
          • Female Condoms
          • Diaphragms
          • Sponges
          • Vaginal Rings
          • Subdermal Implants
          • IUD
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • Drugs
          • Oral Contraceptive Pills
          • Injectables
          • Topical
        • Devices
          • Male Condoms
          • Female Condoms
          • Diaphragms
          • Sponges
          • Vaginal Rings
          • Subdermal Implants
          • IUD
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Type
        • Drugs
          • Oral Contraceptive Pills
          • Injectables
          • Topical
        • Devices
          • Male Condoms
          • Female Condoms
          • Diaphragms
          • Sponges
          • Vaginal Rings
          • Subdermal Implants
          • IUD
    • Middle East:
      • By Type
        • Drugs
          • Oral Contraceptive Pills
          • Injectables
          • Topical
        • Devices
          • Male Condoms
          • Female Condoms
          • Diaphragms
          • Sponges
          • Vaginal Rings
          • Subdermal Implants
          • IUD
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • Drugs
          • Oral Contraceptive Pills
          • Injectables
          • Topical
        • Devices
          • Male Condoms
          • Female Condoms
          • Diaphragms
          • Sponges
          • Vaginal Rings
          • Subdermal Implants
          • IUD
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Evofem Biosciences, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Actavis Generics (Teva Pharmaceutical Industries Ltd.)
    • Sun Pharmaceutical Industries Ltd.
    • Perrigo Company plc
    • Uniprix
    • Gavis Pharmaceuticals (Lupin Limited)
    • Sandoz International GmbH
    • Aurobindo Pharma Limited
    • HRA Pharma
    • Mankind Pharma
    • Other Major Players

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. Global Contraceptives Market, By Type, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • Oral Contraceptive Pills
        • Injectables
        • Topical
    • Devices
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
        • Male Condoms
        • Female Condoms
        • Diaphragms
        • Sponges
        • Vaginal Rings
        • Subdermal Implants
        • IUD
  5. Global Contraceptives Market, By Regions, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  6. Competitive Landscape
    • Company Profiles
      • Evofem Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Actavis Generics (Teva Pharmaceutical Industries Ltd.)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Perrigo Company plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Uniprix
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Gavis Pharmaceuticals (Lupin Limited)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sandoz International GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Aurobindo Pharma Limited
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • HRA Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mankind Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Other Major Players
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 27 figures on “Contraceptives Market – Global forecast to 2027.

Frequently Asked Questions

The global contraceptives market was valued at US$ 24,605.4 Mn in 2019 and is forecast to reach a value of US$ 37,889.0 Mn by 2027 at a CAGR of 5.5% between 2020 and 2027.
Major factor driving the growth of global contraceptives market during the forecast period include increasing population, and increasing focus on family planning.
Major factors hampering the growth of the contraceptives market during the forecast period constitutes of side effects associated with drugs and devices, and low adoption of emergency contraceptives in emerging economies.
Devices held dominant position in the global contraceptives market in 2019.
North America Contraceptives market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., and Pantarhei Bioscience B.V.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner